Research Reports Library

Here you will find copies of HDSA Research Reports that have been featured on the HDSA website and in our print publications. To read or download a report just click on the title.

2012 reports

HD Patient Stem Cells Advance Research

GM1 Restores Motor Function in the YAC128 Mouse

RNAi Safety Studies in Primates

2011 reports

TRACK-HD Identifies Candidate Biomarkers Based on a Two Year Longitudinal Study

The Muscle Relaxant Dantrolene is Neuroprotective in an HD Mouse Model

The Form of the HD Protein Associated with Neurodegeneration is Identified

Melatonin Delays Onset in HD Mouse Model

Biomarker for HD Identified

Oxidation. Oligomerization, Copper, and Protein Clearance: The Prana Trial

KMO Inhibitor Increases Suvival Time by 40 Percent in the HD Mice

Quinazoline Derivative may treat Huntington's disease

Phosphodiesterase-10A inhibitors moving through the pipeline

Progression of Huntington's Disease 

Huntingtin Aggregates Visualized at Oak Ridge Laboratory

KMO Inhibition in Fruitflies

Dr. Ray Truant and Colleagues Publish Promising Findings

A New Mouse Model of HDL2, a very rare disorder similar to HD

Interview with Steven Hersch on the CREST-E Trial

Siena Biotech Starts Phase II Trial of its SIRT1 Inhibitor in Europe

Why Mechanism Matters: The Case of Dimebon

DRP1 Identified as Promising Therapeutic Target

A Drug in Trials for MS is Helpful to HD Mice

A New Drug May be Neuroprotective in HD

Novel Compounds Developed to Protect Brain from Neurodegeneration

New Caspase Six Inhibitors Identified and Optimized

Exercise found harmful in a mouse model of HD


2010 reports

Everolimus not neuroprotective in the R6/2 mice

HART (ACR16) trial results announced - encouraging but not conclusive

Autophagy and Antioxidants

Metalloproteinases - new therapeutic targets

Reduced Creatine Kinase

2010 HDSA Convention Notes: Research Forum

2010 HDSA Convention Notes: Potential New Therapies

Press Release: Prana Biotechnology's PBT2 is in development for HD and AD

Sirtuin Inhibition Achieves Neuroprotection by Decreasing Sterol Biosynthesis

New Insights About Protein Aggregation

Mesenchymal Stem Cells are Helpful in the YAC128 Mouse Models

News from Raptor Pharmaceuticals

Small Molecules Mimic BDNF

CoQ10 and Minocycline Not Helpful in a Mouse Model

Cargo Recognition is Impaired in Autophagy

RNA Interference in a Clinical Trial for Melanoma Patients 

Neurosearch Presents Additional Huntexil (ACR16) Data

Disappointing results in a Phase III Trial of Dimebon in Alzheimer's

Phase II Dimebon results are reported in an academic journal

More on Extrasynaptic Activity and Memantine in the HD Mice

A Sirtuin Inhibitor Enters Phase I Clinical Trials in Europe

A Molecular Switch: Studies of Phosphorylation 


2009 reports

The 2009 Huntington's Disease Clinical Research Symposium

Synaptic Activity, Extrasynaptic Activity, and Memantine

The Search for Genetic Modifiers

Track-HD reports baseline findings

Strattera found ineffective in treating cognition in HD patients

Interview with Jan Nolta on stem cells

Mesenchymal stem cells in an animal model

FDA grants Dimebon orphan drug status

Cogane, a new BDNF inducer, enters the drug pipeline for HD

A breakthrough in generating stem cells from adult cells

The RCAN1-1l gene and HD

Axonal transport is impaired in HD

Rhes and the HD protein

Medivation to begin a Phase III trial of Dimebon

A new caspase six inhibitor is developed

Indiana researchers get NIH funding for HD research

Minocycline Phase II trial results disappointing

Acetylation of the HD protein - a new therapeutic target

An ampakine upregulates BNDF and improves memory

Stem cell research proceeds with hope and caution

Toxic HD protein fragments

Obama signs order lifting the ban on embryonic stem cell research

UPS impairment and HD

More on the PCG-1 alpha gene

The ACR16 trial is enrolling participants

PGC-1 alpha gene modifies age of onset in HD

Advances in RNA interference


2008 reports

Weight loss in Huntington's Disease

Ethyl EPA (Miraxion) still in the pipeline

Huntington Study Group symposium 2008

ACR16 and cysteamine make progress in the pipeline

Nrf2 responsive genes are activated in HD

Ethyl-EPA reduces the rate of brain atrophy  

An HDAC inhibitor ameliorates pathology in the R6/2 mice

Inhibitors of cytochrome c have therapeutic potential

CEP-1347 is added to the research pipeline

The Hereditary Disease Foundation Conference 2008

How Tetrabenazine Works

A New Stem Cell Line for HD: Another Model of the Disease

Dimebon and Alzheimer's

Immune System Over-Activated in HD

The FDA Approves a Phase IIb Clinical Trial of ACR16

Dimebon found safe and well tolerated in a Phase II trial

Sertaline helps two mouse models of HD

Raptor Pharmaceuticals Plan Phase II trial of Cysteamine

ALS clinical trial finds that minocycline accelerates disease progression

The Inaugural HSG Clinical Research Symposium

DIMOND (Dimebon Phase 2 Clinical Research Study) is Recruiting 

first large transgenic animal model for Huntington's disease

Huntington Study Group Meetings Starting the Old and Planning for the New

Enrollment for DIMOND was completed in March 2008. Dimebon clinical trial is recruiting.

2008 CHDI HD Therapeutics Conference - A Report from an HD Family Perspective

Drugs which induce autophagy are added to the research pipeline

Early Neurotransmitter Problems in HD

Physical activity delays onset of motor symptoms in the R6/1 mouse model of HD

ALS clinical trial finds that minocycline accelerates disease progression

Yerkes researchers develop first transgenic nonhuman primate model of Huntington's disease


2007 Essays

The Huntington’s Disease Community’s Strategic Plan for the Cure

Part One

The Huntington’s Disease Community’s Strategic Plan for the Cure

Part Two

The Huntington’s Disease Community’s Strategic Plan for the Cure

Part Three